9 research outputs found

    Human parvovirus B19 associated with idiopathic thrombocytopenic purpura

    No full text
    Although human parvovirus B19 (PVB19) is mainly known to be the causative agent of fifth disease, it is also important in the etiopathogenesis of various hematologic disorders. Recently, its role in the occurrence of chronic anemia and pancytopenia in immunocompromised patients has been revealed. In this study, the authors searched for the presence of PVB19 in a group of patients with idiopathic thrombocytopenic purpura (ITP). The PVB19 DNA was determined by nested PCR, and serologic responses to the virus were evaluated by ELISA. Viral genome was detected by PCR in the sera of 9 of the 19 patients. The IgM and IgG positivities were 57 and 73% in the patients, respectively. These results suggest that PVB19 is associated with ITP nearly in half of the patients and its pathogenetic role in the cases of ITP needs further consideration

    In vitro

    No full text

    Antifungal susceptibilities of dermatophytic agents isolated from clinical specimens

    No full text
    The aim of this study was to investigate the susceptibility to four antifungal agents: ketoconazole, terbinafine, itraconazole and fluconazole, of the different species of dermatophyte strains isolated from clinical specimens. A total of 128 specimens were collected from toe nail, foot, inguinal region, trunk, hands and head. The dermatophytes tested included Trichophyton rubrum 108 (84.4%), Trichophyton mentagrophytes 11 (8.6%), Epidermophyton floccosum 5 (3.9%), Microsporum canis 2 (1.5%) and Trichophyton tonsurans 2 (1.5%). The mean minimum inhibitory concentrations (MIC) for the five species of dermatophytes ranged between 0.09-1.12 mu g/mL for ketoconazole, 0.04-0.27 mu g/mL for terbinafine, 0.08-0.43 mu g/mL for itraconazole and 16.18-24.0 mu g/mL for fluconazole. In vitro analysis of antifungal activity of these agents would also allow for the comparison between different systemic antifungals, which in turn may clarify the reasons for the lack of clinical response or serve as an effective therapy for patients with chronic infection
    corecore